Skip Nav Destination
Issues
1 May 2013
-
Cover Image
Cover Image
Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR) and positively charged polyethylenimine (PEI). Empty nanoparticles were composed of DOPE, linoleic acid, and DMG-PEG. After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
CCR Perspectives in Drug Approval
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Michael Axelson; Ke Liu; Xiaoping Jiang; Kun He; Jian Wang; Hong Zhao; Dubravka Kufrin; Todd Palmby; Zedong Dong; Anne Marie Russell; Sarah Miksinski; Patricia Keegan; Richard Pazdur
Molecular Pathways
Review
Human Cancer Biology
NIK Controls Classical and Alternative NF-κB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells
Lina Odqvist; Margarita Sánchez-Beato; Santiago Montes-Moreno; Esperanza Martín-Sánchez; Raquel Pajares; Lydia Sánchez-Verde; Pablo L. Ortiz-Romero; Jose Rodriguez; Socorro M. Rodríguez-Pinilla; Francisca Iniesta-Martínez; Juan Carlos Solera-Arroyo; Rafael Ramos-Asensio; Teresa Flores; Javier Menarguez Palanca; Federico García Bragado; Purificación Domínguez Franjo; Miguel A. Piris
High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition
Elisabeth Wik; Even Birkeland; Jone Trovik; Henrica M.J. Werner; Erling A. Hoivik; Siv Mjos; Camilla Krakstad; Kanthida Kusonmano; Karen Mauland; Ingunn M. Stefansson; Frederik Holst; Kjell Petersen; Anne M. Oyan; Ronald Simon; Karl H. Kalland; William Ricketts; Lars A. Akslen; Helga B. Salvesen
PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer
Mohammad W. Khan; Ali Keshavarzian; Elias Gounaris; Joshua E. Melson; Eric C. Cheon; Nichole R. Blatner; Zongmin E. Chen; Fu-Nien Tsai; Goo Lee; Hyunji Ryu; Terrence A. Barrett; David J. Bentrem; Philipp Beckhove; Khashayarsha Khazaie
Cancer Therapy: Preclinical
Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Xiaomeng Huang; Sebastian Schwind; Bo Yu; Ramasamy Santhanam; Hongyan Wang; Pia Hoellerbauer; Alice Mims; Rebecca Klisovic; Alison R. Walker; Kenneth K. Chan; William Blum; Danilo Perrotti; John C. Byrd; Clara D. Bloomfield; Michael A. Caligiuri; Robert J. Lee; Ramiro Garzon; Natarajan Muthusamy; Ly James Lee; Guido Marcucci
Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Emilio Cosimo; Alison M. McCaig; Luke J.M. Carter-Brzezinski; Helen Wheadon; Michael T. Leach; Karine Le Ster; Christian Berthou; Emilie Durieu; Nassima Oumata; Hervé Galons; Laurent Meijer; Alison M. Michie
The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
Sneha V. Gupta; Erin Hertlein; Yanhui Lu; Ellen J. Sass; Rosa Lapalombella; Timothy L. Chen; Melanie E. Davis; Jennifer A. Woyach; Amy Lehman; David Jarjoura; John C. Byrd; David M. Lucas
Imaging, Diagnosis, Prognosis
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
Daniel W. Lin; Lisa F. Newcomb; Elissa C. Brown; James D. Brooks; Peter R. Carroll; Ziding Feng; Martin E. Gleave; Raymond S. Lance; Martin G. Sanda; Ian M. Thompson; John T. Wei; Peter S. Nelson; for the Canary Prostate Active Surveillance Study Investigators
Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Qi Zhao; Otavia L. Caballero; Ian D. Davis; Eric Jonasch; Pheroze Tamboli; W.K. Alfred Yung; John N. Weinstein; Kenna Shaw for the TCGA research network; Robert L. Strausberg; Jun Yao
Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors
Antonella Chiechi; Chiara Novello; Giovanna Magagnoli; Emanuel F. Petricoin, III; Jianghong Deng; Maria S. Benassi; Piero Picci; Iosif Vaisman; Virginia Espina; Lance A. Liotta
Cancer Therapy: Clinical
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Josep Tabernero; Rocio Garcia-Carbonero; James Cassidy; Alberto Sobrero; Eric Van Cutsem; Claus-Henning Köhne; Sabine Tejpar; Oleg Gladkov; Irina Davidenko; Ramon Salazar; Liubov Vladimirova; Sergey Cheporov; Olga Burdaeva; Fernando Rivera; Leslie Samuel; Irina Bulavina; Vanessa Potter; Yu-Lin Chang; Nathalie A. Lokker; Peter J. O'Dwyer
Predictive Biomarkers and Personalized Medicine
Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Bertrand Coiffier; Weimin Li; Erin D. Henitz; Jayaprakash D. Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A. Elsayed; Helgi van de Velde; Michael E. Schaffer; Evgenii A. Osmanov; Xiaonan Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko-Jarosinska; Sven de Vos; Michael Crump; Ofer Shpilberg; Pier Luigi Zinzani; Andrew Cakana; Dixie-Lee Esseltine; George Mulligan; Deborah Ricci
PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
Lars Bullinger; Richard F. Schlenk; Marlies Götz; Ursula Botzenhardt; Susanne Hofmann; Annika C. Russ; Anna Babiak; Lu Zhang; Vanessa Schneider; Konstanze Döhner; Michael Schmitt; Hartmut Döhner; Jochen Greiner
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie; Xinying Su; Lin Zhang; Xiaolu Yin; Lili Tang; Xiuhua Zhang; Yanping Xu; Zeren Gao; Kunji Liu; Minhua Zhou; Beirong Gao; Danping Shen; Lianhai Zhang; Jiafu Ji; Paul R. Gavine; Jingchuan Zhang; Elaine Kilgour; Xiaolin Zhang; Qunsheng Ji
Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi; Lecia V. Sequist; Maria E. Arcila; Christine M. Lovly; Xi Chen; Charles M. Rudin; Teresa Moran; David Ross Camidge; Cindy L. Vnencak-Jones; Lynne Berry; Yumei Pan; Hidefumi Sasaki; Jeffrey A. Engelman; Edward B. Garon; Steven M. Dubinett; Wilbur A. Franklin; Gregory J. Riely; Martin L. Sos; Mark G. Kris; Dora Dias-Santagata; Marc Ladanyi; Paul A. Bunn, Jr; William Pao
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds